Inflammatory and metabolic bone disorders of the pelvis

Author(s):  
Richard W. Keen

♦ Avascular Necrosis♦ Paget’s disease♦ Transient Osteoporosis of the Hip.

Rheumatology ◽  
1992 ◽  
Vol 31 (1) ◽  
pp. 35-39 ◽  
Author(s):  
J. Y. REGINSTER ◽  
A. M. JEUGMANS-HUYNEN ◽  
M. WOUTERS ◽  
N. SARLET ◽  
H. D. MCINTYRE ◽  
...  

2021 ◽  
Vol 22 (18) ◽  
pp. 10158
Author(s):  
Marco Paoletta ◽  
Antimo Moretti ◽  
Sara Liguori ◽  
Alessandra Di Paola ◽  
Chiara Tortora ◽  
...  

The role of the endocannabinoid/endovanilloid (EC/EV) system in bone metabolism has recently received attention. Current literature evidences the modulation of osteoclasts and osteoblasts through the activation or inhibition of cannabinoid receptors in various pathological conditions with secondary involvement of bone tissue. However, this role is still unclear in primary bone diseases. Paget’s disease of the bone (PDB) could be considered a disease model for analyzing the role of the EC/EV system on osteoclasts (OCs), speculating the potential use of specific agents targeting this system for managing metabolic bone disorders. The aim of the study is to analyze OCs expression of EC/EV system in patients with PDB and to compare OCs activity between this population and healthy people. Finally, we investigate whether specific agents targeting EC/EV systems are able to modulate OCs activity in this metabolic bone disorder. We found a significant increase in cannabinoid receptor type 2 (CB2) protein expression in patients with PDB, compared to healthy controls. Moreover, we found a significant reduction in multi-nucleated tartrate-resistant acid phosphatase (TRAP)–positive OCs and resorption areas after treatment with JWH-133. CB2 could be a molecular target for reducing the activity of OCs in PDB, opening new therapeutic scenarios for the management of this condition.


2021 ◽  
Vol 11 (10) ◽  
Author(s):  
Shailesh Hadgaonkar ◽  
Shaunak Patwardhan ◽  
Pramod Bhilare ◽  
Parag Sancheti ◽  
Ashok Shyam

Introduction:Paget’s disease of bone (PDB) is a metabolic bone disease presenting as polyostotic or monostotic lesions of the spine. Although common in the Anglo-Saxon population, it is rare on the Indian subcontinent. Neurological complications though infrequent can be severe in pagetic spine. Case Report:We report a case of a polyostotic variant of PDB involving lumbar spine (L2 vertebrae), iliac bones, and femur presenting as chronic low back pain and neurological deficit, i.e., cauda equina syndrome. On initial workup, a diagnosis of PDB was made and given cauda equina compression with neurological deficit, posterior spinal decompression, and biopsy was performed. The histopathological evaluation confirmed the diagnosis and the patient was treated with bisphosphonates for 6 months, along with serial monitoring of alkaline phosphatase levels. Conclusion:Through this case report, we hope to emphasize that PDB should be considered as a possible cause of neurological symptoms at presentation, especially in elderly patients. Also furthermore, early surgical intervention followed by bisphosphonates therapy can lead to favorable outcomes in such patients. Keywords:Polyostotic, Paget’s disease, cauda equine syndrome, lumbar spine.


PLoS ONE ◽  
2019 ◽  
Vol 14 (8) ◽  
pp. e0219662 ◽  
Author(s):  
Yara Haridy ◽  
Florian Witzmann ◽  
Patrick Asbach ◽  
Robert R. Reisz

1986 ◽  
Vol 12 (1) ◽  
pp. 49-70
Author(s):  
Joseph M. Lane ◽  
Joanne R. Werntz ◽  
John H. Healey ◽  
Vincent J. Vigorita

Author(s):  
Gabriella Iannuzzo ◽  
Gianpaolo De Filippo ◽  
Daniela Merlotti ◽  
Veronica Abate ◽  
Alessio Buonaiuto ◽  
...  

AbstractBisphosphonates are the first-choice treatment of osteoporosis and Paget’s disease of bone. Among the bisphosphonates, the non-amino-bisphosphonates, such as clodronic acid, are intracellular converted into toxic analogues of ATP and induce cellular apoptosis whereas the amino-bisphosphonates, such as zoledronic acid, inhibit the farnesyl-diphosphate-synthase, an enzyme of the mevalonate pathway. This pathway regulates cholesterol and glucose homeostasis and is a target for statins. In this retrospective cohort study, we evaluated the effects of an intravenous infusion of zoledronic acid (5 mg) or clodronic acid (1500 mg) on blood lipid (i.e. total cholesterol, low-density lipoprotein-cholesterol, high-density lipoprotein-cholesterol and triglycerides) and glucose levels in patients with osteoporosis and Paget’s disease of bone. All patients were evaluated before, 1 and 6 months after bisphosphonate treatment. Pagetic and osteoporotic patients treated with zoledronic acid showed a significant reduction in glucose and atherogenic lipids during follow-up whereas these phenomena were not observed after clodronic treatment. The effect on circulating lipid levels was similar in naïve and re-treated Pagetic patients. Zoledronic acid treatment was associated with a reduction in blood glucose and atherogenic lipids in patients with metabolic bone disorders. The extent of change was similar to that obtained with the regular assumption of a low-intensity statin. Further studies are warranted to better evaluate the clinical implications of these observations.


Sign in / Sign up

Export Citation Format

Share Document